Explanipedia

Tailored strategy for managing post-cardiac-arrest patients using an early stratification tool: a French university hospital experience Open

Clotilde Bachollet, Alain Cariou, Hélène Caillon, Emmanuel Canet, Jean-Baptiste Lascarrou · 2025

Improving fecal sample collection in patients with inflammatory bowel disease: A comparative evaluation of two calprotectin devices Open

G Pasi, Arini Dewi Antari, Damien Masson, Thomas Dejoie, Marie-Anne Vibet , et al. · 2025

This study demonstrates that a sampling bottle offers a patient-friendly alternative to the conventional stool container, significantly enhancing patient's acceptability with stool collection. These findings support the integration of pati…

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial Open

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj , et al. · 2024

An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients Open

Charissa Wijnands, Gad Armony, Somayya Noori, Jolein Gloerich, Vincent Bonifay , et al. · 2024

Objectives Minimal residual disease (MRD) status in multiple myeloma (MM) is an important prognostic biomarker. Personalized blood-based targeted mass spectrometry detecting M-proteins (MS-MRD) was shown to provide a sensitive and minimall…

M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator Open

Charissa Wijnands, Pieter Langerhorst, Somayya Noori, Jenneke J. Keizer-Garritsen, Hans J. C. T. Wessels , et al. · 2023

Objectives Minimal residual disease status in multiple myeloma is an important prognostic biomarker. Recently, personalized blood-based targeted mass spectrometry (MS-MRD) was shown to provide a sensitive and minimally invasive alternative…

P10 AN ULTRA-SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M-PROTEIN IN PERIPHERAL BLOOD (M-INSIGHT) Open

Vincent Bonifay, Victor Vimard, Somayya Noori, Charissa Wijnands, Cyrille Touzeau , et al. · 2023

With the improvement of therapy (monoclonal antibody, CAR-T), detection of minimal residual disease (MRD) and early restart of therapy is of high importance to manage multiple myeloma disease (MM). Most sensitive MRD assays to date are bas…

B04 IMPLEMENTING M-PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA PATIENTS USING ULTRA-SENSITIVE TARGETED MASS SPECTROMETRY DATA AND AN OFF-THE-SHELF CALIBRATOR Open

Charissa Wijnands, Pieter Langerhorst, Somayya Noori, Jolein Gloerich, Vincent Bonifay , et al. · 2023

Introduction: Minimal residual disease (MRD) detection in Multiple Myeloma (MM) patients currently relies on bone marrow samples. These tests provide important information, but are invasive and not suitable for frequent monitoring. However…

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry Open

Somayya Noori, Charissa Wijnands, Pieter Langerhorst, Vincent Bonifay, Christoph Stingl , et al. · 2023

Molecular Signature of <sup>18</sup>F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study Open

Jean-Baptiste Alberge, Françoise Kraeber‐Bodéré, Bastien Jamet, Cyrille Touzeau, Hélène Caillon , et al. · 2022

The International Myeloma Working Group recently fully incorporated ¹⁸F-FDG PET into multiple myeloma (MM) diagnosis and response evaluation. Moreover, a few studies demonstrated the prognostic value of several biomarkers extrac…

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial Open

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj , et al. · 2021

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow Open

Pieter Langerhorst, Somayya Noori, Marina Zajec, Yolanda B. de Rijke, Jolein Gloerich , et al. · 2021

Background Minimal residual disease (MRD) status assessed on bone marrow aspirates is a major prognostic biomarker in multiple myeloma (MM). In this study we evaluated blood-based targeted mass spectrometry (MS-MRD) as a sensitive, minimal…

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study Open

M. Degez, Hélène Caillon, Anne Chauviré-Drouard, Maxime Leroy, David Lair , et al. · 2021

Background: Endometrial cancer is the most common pelvic gynecological cancer in France. The most frequent symptom is post-menopausal bleeding and is one of the primary reasons for consultation in gynecological emergencies. The treatment i…

Hyponatremia is associated with poor outcome in COVID-19 Open

Hugo De Carvalho, Thibault Letellier, Matilde Karakachoff, Geoffrey Desvaux, Hélène Caillon , et al. · 2021

Gamma heavy chain disease associated with rheumatoid arthritis: a case report Open

G. Danic, Thomas Dejoie, Hélène Caillon, Aurélie Achille, P. Pottier , et al. · 2021

L’hyponatrémie semble être un facteur prédictif d’évolution défavorable dans l’infection COVID-19 Open

Thibault Letellier, Hugo De Carvalho, Matilde Karakachoff, Thomas Dejoie, Hélène Caillon , et al. · 2020

INTRODUCTION: L’hyponatrémie est décrite comme facteur prédictif d’une évolution péjorative dans l’infection à Sars-CoV. Quid du Sars-CoV2 ? DESCRIPTION: L’objectif principal était d’évaluer l’association entre une hyponatrémie (natrémie <…

Hyponatremia is Associated with Poor Outcome in COVID-19 Open

Hugo De Carvalho, Thibault Letellier, Matilde Karakachoff, Geoffrey Desvaux, Hélène Caillon , et al. · 2020

Background Hyponatremia has been described in severe acute respiratory syndrome. Our objective was to describe the impact of hyponatremia on COVID-19 patients’ outcome (intensive care unit [ICU] admission, mechanic ventilation or death). M…

Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial Open

Vincent Dochez, Mélanie Randet, Céline Renaudeau, Jérôme Dimet, Aurélie Le Thuaut , et al. · 2019

Background: Presumed benign ovarian tumours (PBOT) are defined by the International Ovarian Tumour Analysis (IOTA) group, without suspected sonographic criteria of cancer, without ascites or metastasis. The aim is to evaluate the efficacy …

Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial Open

Eileen M. Boyle, Xavier Leleu, Marie-Odile Pétillon, Lionel Karlin, Chantal Doyen , et al. · 2019

Summary Single agent daratumumab has shown clinical activity in relapsed, refractory multiple myeloma (RRMM). The Intergroupe Francophone du Myélome 2014‐04 trial was designed to further investigate daratumumab in combination with dexameth…

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Open

Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj , et al. · 2019

S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS Open

Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj , et al. · 2019

Background: VTd is a standard of care for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients. Daratumumab (DARA), a CD38 mAb, significantly reduced the risk of progression or death and improved complete response (CR) and …

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review Open

Vincent Dochez, Hélène Caillon, E. Vaucel, Jérôme Dimet, Norbert Winer , et al. · 2019

Ovarian cancer is the 5th leading cause of death for women with cancer worldwide. In more than 70% of cases, it is only diagnosed at an advanced stage. Our study aims to give an update on the biological markers for diagnosing ovarian cance…

Eltrombopag induces major non‐toxic hypersiderraemia Open

Hélène Caillon, Pierre Péterlin, Patrice Chevallier, Thierry Guillaume, Amandine Lebourgeois , et al. · 2019

To the Editor We report Eltrombopag treatment as a new aetiology of non-toxic plasmatic iron increase. A 69-year-old woman, who had received an allogeneic stem cell transplantation (allo-SCT) for myelodysplastic syndrome, presented with pe…

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements Open

Thomas Dejoie, Jill Corre, Hélène Caillon, Philippe Moreau, Michel Attal , et al. · 2018

Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center Open

Hélène Caillon, Cécile Tardif, Erwan Dumontet, Norbert Winer, Damien Masson · 2017

The serum sFlt-1/PlGF ratio showed highly predictive performances for ruling out PE. Using these biomarkers in routine management of PE may improve clinical care and avoid inappropriate hospitalization, which has a significant economic imp…

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients Open

Mauricette Michallet, Colette Chapuis‐Cellier, Thomas Dejoie, Christine Lombard, Hélène Caillon , et al. · 2017

Novel anti-myeloma agents have improved patient response rates, which are historically based on reductions of the M-protein. These methods can be inaccurate for quantifying M-proteins at low concentrations. We compared the consistency and …

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14) Open

Cyrille Touzeau, Steven Le Gouill, Beatrice Mahé, Jean Samuel Boudreault, Thomas Gastinne , et al. · 2017

International audience

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma Open

Thomas Dejoie, Jill Corre, Hélène Caillon, Cyrille Hulin, Aurore Perrot , et al. · 2016

Key Points Serum FLC analysis is a more sensitive indicator of disease than urinalysis. Improved sensitivity of serum over urine measurements during monitoring translates into valuable prognostic information.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial Open

Philippe Moreau, Cyrille Hulin, Margaret Macro, Denis Caillot, Carine Chaleteix , et al. · 2016

Key Points The overall response rate following 4 induction cycles of VTD prior to ASCT is higher than that of 4 cycles of VCD.

Leptin and its potential interest in assisted reproduction cycles Open

Aurore Catteau, Hélène Caillon, P. Barrière, M. Denis, David Masson , et al. · 2015

Leptin regulates energy balance and female reproductive function, mainly through its action on hypothalamic-pituitary-ovarian function, whose molecular and cellular aspects are progressively being deciphered. Preliminary studies evaluating…

Hélène Caillon YOU? Author Swipe